Aviva’s AstraZeneca AZN Stock Holding History

Aviva’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.04B	Sell	10,899,700 -187,961	-2%	-$35.4M	3%	6
2026 Q1	$2.15B	Buy	+11,087,661	New	+$2.14B	3.6%	4

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Aviva's AZN Position: Q2 2026 in Review

Aviva reduced its AstraZeneca (AZN) stake by 1.7% in Q2 2026, selling an estimated $35.4M and leaving 10,899,700 shares worth $2.04B. The position accounts for 3% of the portfolio, ranked #6.

Aviva first reported a position in AZN in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.15B in Q1 2026. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Aviva held 10,899,700 shares of AstraZeneca worth $2.04B as of Q2 2026.
Aviva sold 187,961 AstraZeneca shares in Q2 2026, an estimated $35.4M.
AstraZeneca made up 3% of Aviva's portfolio in Q2 2026, its #6 holding.
Aviva first reported a position in AstraZeneca in Q1 2026 and has held it in 2 quarters since.
Aviva's AstraZeneca position peaked at $2.15B in Q1 2026.
1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.